Evidence map›Paper›PMID 27586240›Full record

ArticleBMC systems biology2016

A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes.

Sujuan Wu, Junyi Li, Mushui Cao, Jing Yang, Yi-Xue Li, Yuan-Yuan Li

Open access · diamondAbstract read
In one paragraph

Article in BMC systems biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A new border for circadian rhythm gene NFIL3 in diverse fields of cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  5. Review
  6. Differential gene regulatory networks in development and disease.Cellular and molecular life sciences : CMLS · 2018
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sujuan WuSchool of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Junyi LiShanghai Center for Bioinformation Technology, 1278 Keyuan Road, Shanghai, 201203, China.
Mushui CaoShanghai Center for Bioinformation Technology, 1278 Keyuan Road, Shanghai, 201203, China.
Jing YangSchool of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Yi-Xue LiSchool of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China. yxli@sibs.ac.cn.
Yuan-Yuan LiShanghai Center for Bioinformation Technology, 1278 Keyuan Road, Shanghai, 201203, China. yyli@scbit.org.
Shanghai Center For Bioinformation Technology · CNCenter for Excellence in Molecular Cell Science · CNEast China University of Science and Technology · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma is the most common brain tumor and it has very high mortality rate due to its infiltration and heterogeneity. Precise classification of glioma subtype is essential for proper therapeutic treatment and better clinical prognosis. However, the molecular mechanism of glioma is far from clear and the classical classification methods based on traditional morphologic and histopathologic knowledge are subjective and inconsistent. Recently, classification methods based on molecular characteristics are developed with rapid progress of high throughput technology.

methodsIn the present study, we designed a novel integrated gene coexpression analysis approach, which involves differential coexpression and differential regulation analysis (DCEA and DRA), to investigate glioma prognostic biomarkers and molecular subtypes based on six glioma transcriptome data sets.

resultsWe revealed a novel three-transcription-factor signature including AHR, NFIL3 and ZNF423 for glioma molecular subtypes. This three-TF signature clusters glioma patients into three major subtypes (ZG, NG and IG subtypes) which are significantly different in patient survival as well as transcriptomic patterns. Notably, ZG subtype is featured with higher expression of ZNF423 and has better prognosis with younger age at diagnosis. NG subtype is associated with higher expression of NFIL3 and AHR, and has worse prognosis with elder age at diagnosis. According to our inferred differential networking information and previously reported signalling knowledge, we suggested testable hypotheses on the roles of AHR and NFIL3 in glioma carcinogenesis.

conclusionsWith so far the least biomarkers, our approach not only provides a novel glioma prognostic molecular classification scheme, but also helps to explore its dysregulation mechanisms. Our work is extendable to prognosis-related classification and signature identification in other cancer researches.

Indexed as

Gene Expression ProfilingBiomarkers, TumorComputational BiologyGliomaHumansMachine LearningPrognosisTranscription FactorsBiomarkers, TumorTranscription FactorsDifferential coexpression analysisDifferential regulation analysisGlioma carcinogenesisGlioma molecular classificationPrognostic biomarker

Identifiers

PMID27586240
PMCPMC5009532
OpenAlexW2508753416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.